manufacture bulk controlled substances for sale to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Chattem Chemicals, Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Chattem Chemicals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: August 16, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–16860 Filed 8–24–07; 8:45 am] BILLING CODE 4410–09–P

## DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 3, 2007, Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
4-Methoxyamphetamine (7411) Dihydromorphine (9145)	
Difenoxin (9168)	I
Amphetamine (1100)	Ш
Methamphetamine (1105)	11
Methylphenidate (1724)	
Pentobarbital (2270) Codeine (9050)	
Dihydrocodeine (9120)	
Oxycodone (9143)	II
Hydromorphone (9150)	П
Hydrocodone (9193)	II
Meperidine (9230)	II

Drug	Schedule
Dextropropoxyphene, bulk (non- dosage forms) (9273).	II
Morphine (9300)	П
Thebaine (9333)	П
Oxymorphone (9652)	П
Noroxymorphone (9668)	П
Alfentanil (9737)	П
Sufentanil (9740)	П
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 26, 2007.

Dated: August 16, 2007.

#### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–16873 Filed 8–24–07; 8:45 am] BILLING CODE 4410–09–P

# **DEPARTMENT OF JUSTICE**

## **Drug Enforcement Administration**

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 30, 2007, Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II.

The company plans to manufacture small quantities of the above listed controlled substance for distribution to its customers for the purpose of research.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 26, 2007.

Dated: August 16, 2007.

#### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–16854 Filed 8–24–07; 8:45 am] BILLING CODE 4410–09–P

# DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

## Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on July 19, 2007, CIMA Labs, Inc., 10000 Valley View Road, Attention: Jason Gardner, Eden Prairie, Minnesota 55344, made application by letter to the Drug Enforcement Administration (DEA) to be registered as an importer of Nabilone (7379), a basic class of controlled substance listed in schedule II.

The company plans to import the basic class of controlled substance for clinical trials and research.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 26, 2007.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substance listed in schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.

Dated: August 16, 2007.

#### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7-16871 Filed 8-24-07; 8:45 am] BILLING CODE 4410-09-P

## DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 27, 2007, Cody Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Dihydromorphine (9145) Amphetamine (1100) Methamphetamine (1105) Amobarbital (2125) Pentobarbital (2270) Secobarbital (2315) Phenylacetone (8501) Cocaine (9041)	
Codeine (9050)	П

Drug	Schedule	Drug	Schedule
Dihydrocodeine (9120)   Oxycodone (9143)   Hydromorphone (9150)   Diphenoxylate (9170)   Meperidine (9230)   Methadone (9250)   Oxymorphone (9652)   Alfentanil (9737)		Hydromorphone (9150)   Hydrocodone (9193)   Morphine (9300)   Thebaine (9333)   Opium, raw (9600)   Opium poppy (9650)   Oxymorphone (9652)	    
Sufentanil (9740)		Sufentanil (9740)	П
Fentanyl (9801)	П	Carfentanil (9743)	
			11

The company plans on manufacturing the listed controlled substances in bulk for sale to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 26, 2007.

Dated: August 16, 2007.

# Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-16874 Filed 8-24-07; 8:45 am]

BILLING CODE 4410-09-P

#### DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated May 7, 2007, and published in the Federal Register on May 14, 2007, (72 FR 27151), Noramco Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Codeine-N-Oxide (9053) Morphine-N-Oxide (9307) Amphetamine (1100) Methylphenidate (1724) Codeine (9050) Dihydrocodeine (9120)	

Sufentanil (9740) II Carfentanil (9743) II Fentanyl (9801) II		
The company plans to manufacture		
small quantities of the Schedule I		
controlled substances for internal		
testing; the Schedule II controlled		
substances will be manufactured in bulk		

for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Noramco, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. §823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: August 16, 2007.

#### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7-16858 Filed 8-24-07; 8:45 am]

BILLING CODE 4410-09-P

## **DEPARTMENT OF LABOR**

#### Office of the Secretary

## Submission for OMB Review: **Comment Request**

August 22, 2007.

The Department of Labor has submitted the following public information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104–13, 44 U.S.C. chapter 35). Copies of this ICR, with applicable supporting documentation; including among other